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Graphical Abstract 
 
Highlights 
 Arginine-based surfactant Bz-Arg-NHC12 has both hemolytic and antihemolytic effects. 
 Both processes depend on the lipid composition of the erythrocyte membrane. 
 SRBC is more resistant than HRBC to the hemolytic effect of the surfactant. 
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 The degree of protection showed for SRBC was about 50% lower than for HRBC. 
 HRBC could respond to osmotic stress by releasing membrane lipids to the medium. 
*Corresponding author. E-mail: lbakas@biol.unlp.edu.ar, morcelle@gmail.com 
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ABSTRACT 
A novel arginine-based cationic surfactant Nα-benzoyl-arginine dodecylamide (Bz-Arg-NHC12) 
was synthesized in our laboratory. In this paper we study the interaction of Bz-Arg-NHC12 with 
sheep and human red blood cells (SRBC and HRBC respectively) due to their different 
membrane physicochemical/biophysical properties. SRBC demonstrated to be slightly more 
resistant than HRBC to the hemolytic effect of the surfactant, being the micellar structure 
responsible for the hemolytic effect in both cases. Moreover, besides the hemolytic effect, a 
dual behavior was observed for the surfactant studied: Bz-Arg-NHC12 was also able to protect 
red blood cells against hypotonic lysis for HRBC in a wide range of surfactant concentrations. 
However, the degree of protection showed for SRBC was about 50% lower than for HBRC. In 
this regard, a remarkable volume expansion was evidenced only for SRBC treated with Bz-
Arg-NHC12, although no correlation with the antihemolytic potency (pAH) was found. On the 
contrary, our surfactant showed a greater pAH when human erythrocytes were submitted to 
hypotonic stress, with a low volume expansion, showing a higher amount of solubilized 
phospholipids in the supernatant when compared with SRBC behavior. Surface plasmon 
resonance measurements show the molecular interaction of the surfactant with lipid bilayers 
from HRBC and SRBC lipids, demonstrating that in the latter neither microvesicle release or 
lipid extraction occurred. Our results demonstrate that the volume expansion of erythrocytes is 
not the only mechanism responsible for the protection by surfactants against hypotonic 
hemolysis: volume expansion could be compensated via microvesicle release or by the 
extraction of membrane components upon collisions between red blood cells and surfactant 
aggregates depending on the membrane composition. 
Keywords: Amino acid-based surfactants; hemolysis; antihemolytic potency; membrane 
physicochemical properties; microvesicles. 
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1. INTRODUCTION 
Surfactants are ingredients included in many products used in pharmaceutical formulations and 
cosmetics, particularly in topical and transdermal administration of different active compounds. 
Skin delivery offers many advantages over conventional oral and invasive techniques of drug 
delivery such as its simplicity and convenience. However, its efficiency is restricted by the 
barrier function of the stratum corneum (SC), which structure is analogous to a wall: 
corneocytes are embedded in multiple lipid bilayers of ceramides, fatty acids, cholesterol and 
cholesterol esters [1]. These bilayers form regions of semicrystalline, gel and liquid crystals 
domains, establishing intercellular micro-routes through which many molecules can easily 
penetrate. Significant attention has been paid to the development of more effective methods in 
order to improve skin drug delivery kinetics and broaden the range of drugs that can be 
administrated through transdermal permeation [2]. Among them, penetration enhancers can 
increase skin permeability via different mechanisms, including enhanced drug solubility, 
increased partitioning into the SC, and reversible alteration of the lipid region of the SC, either 
through lipid extraction, fluidization of its crystalline structure or introduction of other modes 
of structural reorganization [3]. Surfactants (anionic, cationic and nonionic) represent one of 
the most commonly used penetration enhancers applied in the pharmaceutical industry [4]. 
In the particular case of surfactants, they can increase the solubility and mobility of hydrophobic 
or organic compounds through the stratum corneum [2]. However, irritation and damage to the 
skin barrier is mainly associated with ionic surfactants. Those surfactants resembling biological 
amphiphiles have demonstrated the ability to influence permeation and increase drug transport 
through the skin, and therefore are promising candidates to be incorporated as penetration 
enhancers in skin delivery formulations [5]. Among this kind of tensioactives, bio-based 
surfactants are synthetic compounds based on natural amphipathic structures such as 
glycolipids, lipopeptides, phospholipids and fatty acids. Lipo-amino acids have been 
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exhaustively studied, demonstrating good surface activity and aggregation properties, broad 
biological activity, and low toxicity profile [6]. In particular, arginine based surfactants are a 
remarkable group of cationic surfactants with antimicrobial activity against a broad spectrum 
of bacteria and fungi, enhanced biodegradability and low toxicity. Consequently, arginine-
based surfactants have been proposed as an alternative to quaternary ammonium halides, which 
have a questionable intrinsic toxicity as well as a questioned biodegradability [7,8]. 
A novel arginine-based cationic surfactant was synthesized in our laboratory using papain (an 
endopeptidase from Carica papaya latex) adsorbed onto polyamide as biocatalyst. The classical 
substrate Nα-benzoyl-arginine ethyl ester hydrochloride (BAEE) was the arginine donor, 
whereas dodecylamine was used as nucleophile for the condensation reaction. The final 
product, Nα-benzoyl-arginine dodecylamide (Bz-Arg-NHC12, Fig. 1), has shown antimicrobial 
activity against both Gram-positive and Gram- negative bacteria, revealing its potential use as 
preservative and effective disinfectant, as it was able to reduce 99% the initial bacterial 
population after only one hour of contact [9]. Bz-Arg-NHC12 demonstrated lower hemolytic 
activity and was less eye-irritating than the commercial cationic surfactant cetrimide. A similar 
trend was also observed when the in vitro cytotoxicity was tested against hepatocytes (HepG2) 
and fibroblasts (1BR.3.G) cell cultures, proving that Bz-Arg-NHC12 was less toxic than 
Cetrimide [9]. Recently, the antifungal activity of this compound was also described against 
phytopathogenic strains [10]. 
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Fig 1. Nα-benzoyl-arginine dodecylamide (Bz-Arg-NHC12) chemical formula. 
Erythrocyte membranes are commonly used as a simplified model system to study the 
interaction of surfactants with biological membranes. In this paper we studied the 
lytic/protective effect of Bz-Arg-NHC12 on sheep and human red blood cells (SRBC and HRBC 
respectively) due to their differences in membrane lipid composition. It is important to consider 
that ruminants are mammals with a unique and striking phospholipid organization in red blood 
cell membranes, lacking phosphatidylcholine (PC, the most abundant phospholipid in other 
mammals' red blood cell membranes) and having high levels of sphingomyelin (SM) and 
cholesterol (CHO). All these characteristics causes the membrane to have a high degree of lipid 
order [11,12], which is more similar to the one described on the lipid matrix of the skin in 
comparison to the lipid order of HRBC membranes. 
In this context, the aim of this work is to gain a deeper insight into the hemolytic and hypotonic 
hemolysis protection mechanisms of Bz-Arg-NHC12 as an estimation of surfactant-membrane 
interaction and toxicity assessment. To this end, we evaluate the dependence of both processes 
on the lipid composition of the erythrocyte membrane. Moreover, the hemolytic and 
antihemolytic mechanisms involved would give valuable information concerning to a general 
toxicological mechanism, providing a hot spot to focus considering the potential use of amino 
acid-based surfactants in biomedical applications. 
2. MATERIALS AND METHODS 
2.1. Ethics Statement 
Blood from healthy sheep was obtained following the protocol approved by the Research Ethics 
Committee of the Facultad de Ciencias Veterinarias of the Universidad Nacional de La Plata 
(CICUAL 129/09) in accordance with the international guidelines for the care and use of 
laboratory animals. Human blood was obtained by venipuncture of healthy volunteers from our 
laboratory staff (CIPROVE, La Plata, Argentina) who gave the appropriate informed consent. 
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All this procedure was approved by the Comité de Bioética y Ética de la Investigación de la 
Facultad de Ciencias Médicas de la Universidad Nacional de La Plata (COBIMED) according 
to the requirements of the Declaration of Helsinki and the Argentinean legislation concerning 
Public Health (laws 25326 and 26529). EDTA was used to prevent blood clotting in both cases. 
2.2. Surfactant synthesis 
Bz-Arg-NHC12 was synthesized in our laboratory using papain, an endopeptidase from Carica 
papaya latex, adsorbed onto polyamide as biocatalyst according to Fait et al.(2015) [9]. 
2.3. Preparation of red blood cells suspensions 
Red blood cells (RBC) were separated from sheep and human blood by centrifugation at 1300×g 
for 15 min at room temperature and washed three times with phosphate buffer solution (PBS) 
containing 123.3 mM NaCl, 22.2 mM Na2HPO4 and 5.6 mM KH2PO4 in MilliQ® nanopure 
water (pH 7.4; 300 mOsm/L).  
2.4. Hemolysis assays 
Aliquots of each RBC suspension (25 μL) were exposed to different concentrations of the 
surfactant dissolved in PBS (1 mL) at a final hematocrit (Ht) of 2%. Samples were incubated at 
37°C for 10 min and then centrifuged at 1300×g for 10 min. Finally, the extent of hemolysis 
was quantified spectrophotometrically measuring the hemoglobin release to the supernatant at 
540 nm, and contrasted to the supernatant of RBC treated with MilliQ® nanopure water (100% 
hemolysis) [13]. A sigmoidal (Boltzmann) fit was applied to dose-response curves using the 
OriginPro 8® software and the concentration inducing 50% hemolysis (HC50) was calculated 
for each compound. 
2.5. Protection against hypotonic hemolysis evaluation 
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Surfactant's protection against hypotonic hemolysis was examined in hypotonic PBS, diluted 
to an osmolarity so that untreated samples (absence of the surfactant) showed 80–90% of 
hemolysis (127 mOsm/L for HRBC and 150 mOsm/L for SRBC) [14]. RBC suspensions (25 
µL) were incubated with different concentrations of the surfactant, dissolved in hypotonic PBS 
(1 mL) for 10 min at 37°C with constant shaking. Intact cells were separated by centrifugation 
at 1300×g for 10 min, and the extent of hemolysis in the supernatant was determined as 
previously described. Each experiment was performed at least three times using three replicate 
samples for each surfactant concentration tested. Statistical analyses were conducted using one-
way analysis of variance (ANOVA) to determine the differences between the data sets, followed 
by Tukey’s post hoc tests for multiple comparisons using the GraphPad Prism® software. 
P<0.05 was considered to denote significance. The surfactant’s concentrations resulting in the 
maximum protection against hypotonic hemolysis (cAHmax) were estimated from the dose-
response curves and the antihemolytic potency (pAH) was expressed as the hemolysis reduction 
percentage compared to untreated samples. Additionally, morphological changes in both HRBC 
and SRBC treated with the surfactant at the corresponding cAHmax were studied using an optical 
microscope (Nikon Eclipse TS100). Images were acquired with a Nikon 391CU 3.2M CCD 
digital camera and analyzed by means of the Micrometrics SE Premium® software. 
2.6. Erythrocyte volume expansion calculation  
Volume expansion determination of HRBC and SRBC treated with the surfactant was carried 
out according to Nogueira et al. (2012) [15].Osmolarities inducing 50% of hemolysis (C50) 
were calculated from the hemolysis vs. medium osmolarity plots obtained for HRBC and SRBC 
incubated in the presence of Bz-Arg-NHC12 at the corresponding cAHmax (supplementary 
material). Theoretical calculations of the volume expansion induced by the surfactant were 
carried out according to Ponder (1948) [16], who proposed that the relation between the critical 
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hemolytic volume (Vh) and the osmotic concentration inducing 50% hemolysis (C50) is 
described by Eq. (1): 
𝑉ℎ = 𝑉𝑛𝑎 +  𝑉𝑎 ×
𝐶𝑖𝑠𝑜
𝐶50
  (1) 
Where Vna is the osmotically non-active volume, representing 30% of the normal RBC volume 
(V0); Va is the osmotically active part of the RBC volume, representing 70% of V0; and Ciso is 
the isotonic concentration (300 mOsm/L). Considering V0 = 98 and 34 fL, Vna = 29.4 and 10.2 
fL and Va = 68.6 and 23.8 fL for HRBC and SRBC, respectively. V0 was measured by 
introducing a blood sample into a Mindray BC-3000 Plus Auto Hematology Analyzer 
(Shenzhen, China). Percentage of volume expansion was calculated comparing the Vh of control 
and treated cells. 
2.7. Membrane solubilization analysis 
The extent of solubilized phospholipids (PLs) was analyzed in the supernatant of HRBC and 
SRBC incubated with Bz-Arg-NHC12. Aliquots of the erythrocyte suspensions previously 
prepared (25 µL) were exposed to surfactant at different concentrations, both below and above 
the corresponding CMC, dissolved in isotonic PBS (1 mL). After 10 min incubation at 37°C, 
supernatant was separated from intact cells by centrifugation (1300×g, 10 min) and hemoglobin 
release was spectrophotometrically determined as previously described. PLs were extracted 
from the supernatant using a mixture of chloroform:methanol (2:1). Finally, organic phase was 
separated and evaporated in a SpeedVac and the amount of PLs were quantified 
spectrophotometrically by a phosphate assay [17]. 
2.8. Surface plasmon resonance (SPR) measurements 
SPR measurements were performed in MP-SPR Navi™ 200 (BioNavis, Finland). The 
instrument comprises a dual-channel detection system with simultaneous measurement in two 
flow cells with an angular-scan range of 40–78 degrees. The device is equipped with two 
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independent lasers (670 and 785 nm) in both channels. Typical flows employed were 10-500 
µL/min and all solutions were prepared with MilliQ® nanopure water. 
2.8.1. Preparation of the sensor surfaces 
Commercial gold substrates (SPR102-AU) were purchased from Bionavis™. Prior to use, the 
gold substrates were washed with NH3:H2O2:H2O (1:1:2) at 90°C during 10 min, rinsed with 
water and ethanol and dried with N2. DL-dithiothreitol (DTT) covered gold substrates were 
prepared by incubation of the bare substrates on 50 µM DTT ethanolic solution for 30 min at 
room temperature. The DTT-gold substrates were immediately rinsed with ethanol and dried 
with N2. 
2.8.2. Liposome binding 
Small unilamellar vesicles (SUVs) prepared from lipids of HRBC and SRBC were employed 
to prepare supported bilayers. Briefly, RBC ghosts were obtained by hypotonic lysis (buffer 
Tris 5 mM, pH 7.4) for 30 min at 4°C from RBC stock suspensions (1 mL). After centrifugation 
at 10000×g for 15 min at 4°C, the supernatant was removed and the ghosts were washed several 
times with lysis buffer till the supernatant remained clear, free of hemoglobin. Total lipids were 
then extracted from the RBC ghosts by the procedure of Folch et al. (1957) [18]. The organic 
phase was separated and dried by evaporating the solvent under a stream of nitrogen and then 
placing the samples under high vacuum for 2 h. Multilamellar vesicles (MLVs) were prepared 
by hydrating the RBC lipids in 20 mM Tris, 150 mM NaCl, pH 7.4 (TBS buffer), prepared with 
high-purity water (Millipore SuperQ). Finally, SUVs were obtained by sonication of the MLVs 
for 30 min and used for the in situ generation of lipid bilayers on the surface of the SPR sensor 
chip. DTT-gold substrates were placed in the SPR device and the SPR curves (from 52 to 78 
degrees) were registered each 3.5 s. The running buffer was TBS with Ca2+ 3 mM at a flow of 
10 µL/min. After 10 min of baseline stabilization, the liposome suspension 0.2 mg/mL was 
injected at 10 µL/min during 20 min in both flow cells. After 10 min of stabilization, a quick 
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pulse of running buffer at 500 µL/min was performed in order to remove weakly adsorbed 
material. The amount of bound lipid was calculated from the change in signal at the angle of 
maximum derivative (ΔΘbilayer) from the initial baseline and the final baseline. ΔΘbilayer were 
employed to normalize the results in different experiments, with typical values around ΔΘ~0.5. 
2.8.3. Surfactant affinity measurements 
After supported bilayer preparation, surfactant solutions of 125, 250 and 500 µM in TBS buffer 
with DMSO 3% were injected at 10 µL/min during 25 min through the main channel while 
buffer (TBS + DMSO 3%) was injected in the control channel. Measurements were made by 
duplicate in freshly made supported bilayers. 
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3. RESULTS AND DISCUSSION 
3.1. Effect of Bz-Arg-NHC12 on red blood cells 
In order to clarify the relationship between the membrane's biophysical properties and the 
hemolytic and antihemolytic mechanisms induced by Bz-ArgNHC12, we analyzed the 
susceptibility of RBC isolated from two different species (sheep and human) to this arginine-
based surfactant. Despite their relative simplicity (i.e. absence of nucleus and organelles), RBC 
have enough functions in common with more specialized cells, and the given results may be 
good indicators of the biological activity of the surfactants at physiological conditions [15]. 
Within this context, SRBC and HRBC were selected as model systems based on their 
differences in the molar proportions of the major lipid classes in the RBC’s membranes. Briefly, 
although the cholesterol (CHO) content was roughly similar among both RBC membranes, the 
main difference was found in the relative amounts of PC and SM: SRBC are known to have a 
higher proportion of SM in their membranes (~42%) than HRBC (12%), while the highest 
amount of PC is found in HRBC (17%) since SRBC membranes lack of this lipid in their 
composition. In addition, the molar ratio of PE, PS and PI together was only slightly different 
between the lipid content of the RBC membranes of both species [11,12]. 
Characterization and quantification of the biological membrane interactions of the surfactants 
was conducted by hemolysis studies. It is widely accepted that the measurement of hemoglobin 
release from RBC is a reliable experimental approach to studying plasma membrane 
permeabilization by various chemical compounds. Furthermore, the evaluation of the hemolytic 
activity of surfactants is a process of fundamental and practical importance, and can be used as 
a means for their toxicological assessment which is especially significant for their medical 
applications [19]. 
In this regard, Bz-Arg-NHC12 showed hemolytic activity against both HRBC and SRBC in 
isotonic medium. The extent of hemolysis obtained at different surfactant concentrations was 
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presented in a dose-response plot (Fig. 2), from which HC50 values were obtained (Table 1). 
The HC50/CMC ratio was also calculated, since it gives a hint about the surfactant’s form 
responsible for the hemolytic effect. Considering the CMC value calculated for Bz-Arg-NHC12 
was 0.085 mM [20], HC50/CMC ratios for HRBC and SRBC were 16.6 and 18.7 respectively. 
This data suggests that SRBC are slightly more resistant than HRBC to hemolysis induced by 
the surfactant, and that its micellar form would be the entity responsible for the hemolytic effect 
in both cases. However, differences in the shape of the dose-response curves were evidenced 
(Fig. 2), reflecting an influence of the membrane biophysical properties on the mechanism 
involved. 
 
Fig. 2. Hemolysis induced by Bz-Arg-NHC12 in human and sheep red blood cells (HRBC and 
SRBC respectively). Values are plotted as the mean ± SD of three independent experiments. 
3.2. Effect of Bz-Arg-NHC12 on the resistance of RBC towards hypotonically induced lysis 
Concentration-dependent surfactant effects on erythrocyte membranes are well known. 
Amphiphiles induce shape alterations, vesiculation and hemolysis in RBC in isotonic media. In 
addition, at low surfactant/lipid molar ratios and in hypotonic media, some surfactants have the 
capability to protect erythrocytes against osmotic lysis [21,22]. Within this context, the 
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influence of surfactants on the cellular osmotic resistance can be used as an index of plasma 
membrane interactions. 
In order to assess the ability of Bz-Arg-NHC12 to protect RBC against hypotonic hemolysis, 
experiments were conducted in hypotonic PBS buffer at a concentration at which approximately 
80-90% of hemolysis was observed for untreated RBC after 10 min incubation at 37°C. Results 
revealed that in the presence of Bz-Arg-NHC12 at different concentrations, protection of HRBC 
and SRBC against hypotonic lysis was observed (Fig. 3). In each case, the maximum protective 
concentration for Bz-Arg-NHC12 (cAHmax) was determined from the dose-response curves as 
described in the materials and methods section. cAHmax values together with the antihemolytic 
potency (pAH) are listed in Table 1. 
 
Fig. 3. Antihemolysis profiles showing hypotonically induced hemolysis dependence on Bz-
Arg-NHC12 concentration (logarithmic scale) for HRBC and SRBC. Straight horizontal lines 
correspond to the percentage of hemolysis of untreated RBC in hypotonic medium (127 
mOsm/L and 150 mOsm/L for HRBC and SRBC, respectively). Values are plotted as the mean 
± SD of three independent experiments. The vertical dotted line indicates the surfactant 
concentration corresponding to CMC. 
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cAHmax values obtained corresponded to 47.5% and 21.0% of the corresponding HC50 for 
HBRC and SRBC respectively. In both cases, the interaction of the surfactant with the plasma 
membrane allows the cell to resist hypotonic media before solubilization/lysis begins. As the 
HC50, cAHmax values for RBC of both species were higher than the CMC (Table 1). Thus, a 
dual behavior was observed for the surfactant studied, showing a wider range of protective 
concentrations when HRBC were tested. Furthermore, the degree of protection (described by 
the cAHmax and pAH values) of Bz-Arg-NHC12 for SRBC was about 50% lower than the one 
registered for HRBC, showing a rapid increase in the extent of hemolysis beyond the cAHmax.  
The antihemolytic mechanism induced by surfactants in hypotonic media is still not fully 
understood but two potential mechanisms have been proposed [22]. On the one hand, the 
surfactant monomer insertion leads to a membrane enlargement by decreasing the lateral 
membrane tension, which allows RBC to swell, increasing their critical lytic volume before the 
leakage. On the other hand, another possible explanation would be that the increase in the 
membrane ionic permeability induced by surfactants leads to transmembrane flip–flop rate 
changes and morphological alterations. Consequently, the equilibrium of ion concentrations 
inside and outside the cell is modified, which reduces the hypotonic hemolysis. 
In order to clarify the mechanism involved in the case of Bz-Arg-NHC12, the theoretical 
calculation of the RBC volume expansion was performed using the relation proposed by Ponder 
(1948) as described by Eq. 1 in the methodology section [16]. Results are presented in Table 1. 
In this regard, the volume expansion of HBRC induced by Bz-Arg-NHC12 was around 4%. 
Surprisingly, for SRBC treated with the surfactant, a remarkable volume expansion was 
evidenced, although no correlation with the antihemolytic potency was found. Our results 
indicate that an increase in the critical hemolytic volume is not a general mechanism responsible 
for the Bz-Arg-NHC12 antihemolytic activity. 
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Nogueira et al.(2012) reported results about the effect of another class of amino acid-based 
surfactants on the resistance of erythrocytes against hypotonically induced lysis [15]. Their 
results support that the surfactant-membrane interactions in isotonic medium (hemolysis) were 
first conducted by the cationic charge density and position rather than by the hydrophobicity 
(given by the alkyl chain length) of the surfactant molecules. On the contrary, this was not the 
case for the antihemolytic effect, in which instance the hydrophobicity of the compounds had a 
greater influence. In their study, both hemolytic and antihemolytic activities were tested against 
human and rat RBC. It is worth noticing their findings corroborate previous studies, in which 
erythrocytes from different species —having specific phospholipid composition and 
mechanical properties of the cytoskeleton [23,24]— also had distinctive hemolytic behavior in 
the presence of surfactants [25,26]. However, no connection between the hemolytic and 
antihemolytic behavior of the surfactants studied and the physicochemical properties of 
membrane have been proposed. In regard to the protection against hypotonic lysis induced by 
the surfactants, Nogueira et al, found no direct correlation between the antihemolytic profile —
given by the shape of the dose-response curves in hypotonic medium— and antihemolytic 
potency (pAH). Moreover, they found no significant correspondence between the antihemolytic 
potency and cell volume expansion for all surfactants tested. According to their conclusions, 
the increased membrane fluidity observed in hypotonic conditions, together with the cell 
volume expansion, might support the mechanism involving the enlargement of the stretching 
capacity of the membrane together with changes in its ionic permeability [15]. 
Moreover they reported a significant correlation between the antihemolytic potency and the 
CMC of the lysine based surfactants for rat RBCs, but not for HRBC. On the other hand the 
CMC correlated with cell volume expansion in human RBC, but not in rat RBC. However, the 
different behavior between rat and human erythrocytes is not exhaustively explained. 
Ultimately, they conclude that the ability of this group of lysine-based surfactants to protect 
against hypotonic hemolysis correlates, in general, directly with the CMC and inversely with 
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the alkyl chain length of the product, depending the surfactant-mediated hemolysis protection 
on the monomer form and not on the micellar structures. Our findings are contradictory to these 
results, since the antihemolytic activity of Bz-Arg-NHC12 was evidenced mainly at surfactant 
concentrations above the CMC (Fig. 3). 
3.3. Solubilization of phospholipids by Bz-Arg-NHC12 
In order to correlate the lack of volume expansion results and the antihemolytic potency of Bz-
Arg-NHC12 observed for HRBC with an alternative mechanism involving lipid extraction —
such as the shedding of microvesicles or lipid extraction upon micellar collisions due to the 
presence of surfactant micelles—, solubilized phospholipids (PLs) were quantified in the 
supernatant of RBC from both species incubated in the presence of the surfactant. 
Fig. 4 shows percentage of hemolysis and solubilization of HRBC and SRBC membranes 
induced by Bz-Arg-NHC12 at concentrations both below and above the CMC. Results 
evidenced that the amount of PLs in the supernatant of HRBC treated with our surfactant was 
significantly higher than that attained for SRBC, giving an insight on the reason why there is 
no volume expansion in this case despite the higher pAH observed. 
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Fig. 4. Hemolysis and membrane solubilization —assayed as phospholipid solubilization— of 
human (Panel a) and sheep (Panel b) red blood cells treated with Bz-Arg-NHC12. Values are 
plotted as the mean ± SD of three independent experiments. 
This finding supports the idea that volume expansion would not be the main mechanism of 
protection against hypotonic hemolysis in the case of HRBC treated with Bz-Arg-NHC12. 
Instead, HRBC could respond to osmotic stress by releasing membrane lipids to the medium, 
either by induced exovesiculation or by lipid extraction upon collisions with surfactant micelles 
present in the surrounding medium. This process could lead to some hemoglobin leakage 
without complete cell lysis. 
As we previously demonstrated, HRBC irreversibly lose surface area and volume due to 
exovesiculation induced byBz-Arg-NHC12 [20]. When incorporated into the membrane, this 
kind of arginine-based compound—having a bulky head with a benzoyl group attached to it— 
are unable to equilibrate rapidly between the outer- and the inner-membrane monolayers. 
Consequently, and in order to compensate the expansion of the outer monolayer without 
compromising the bilayer structure, microvesicles are released and a shape transition from 
discocyte to echinocyte takes place (Fig. 5). Our hypothesis is that exovesiculation can be also 
observed in the case of protection against hypotonically induced hemolysis by Bz-Arg-NHC12, 
explaining the ability of HRBC to resist hypotonic lysis despite the absence of cell volume 
expansion. Furthermore, no microvesicle release was observed when SRBC were incubated in 
the presence of Bz-Arg-NHC12 (data not shown). As a matter of fact, it is important to point out 
that when SRBC were treated with Ca2+ and ionophore A23187 no detectable microvesicles 
were found in the supernatant, indicating that SRBC’s membrane lipid composition is a 
restraining factor for microvesicle release [27]. That is, different mechanisms can be involved 
in the protection against hypotonic hemolysis induced by a given surfactant, depending not only 
on the surfactant’s hydrophobicity, and cationic charge density and position, but also on the 
membrane’s composition. 
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Fig 5. Representative optical-microscopy images (1000×) showing morphological changes in 
human (Panel a) and sheep (Panel b) erythrocytes induced by Bz-Arg-NHC12 at the 
corresponding cAHmax (672.1 and 336.1 μM, respectively). 
3.4. Interaction between surfactant and membrane lipids measured by SPR 
SPR constitutes a powerful biosensing technique for monitoring biomolecular interactions in 
real-time without labeling requirements. Biosensor experiments involve immobilizing one 
reactant on a surface and monitoring its interaction with a second component in solution. SPR 
biosensors measure the change in refractive index of the solvent near the surface that occurs 
during complex formation or dissociation [28]. 
Using supported lipid bilayers and SPR spectroscopy, we tested the binding and lipid 
mobilization capacity of Bz-Arg-NHC12 on HRBC and SRBC membranes. For that purpose, 
lipids were extracted from RBC and immobilized forming a bilayer onto the surface of a sensor 
chip. Following injection of 125 µM of Bz-Arg-NHC12 on chips covered with lipids extracted 
from HRBC (Fig. 6, Panel a) a drop of the signal below the baseline was observed, indicating 
the removal of membrane lipids from the chip. When the concentration of Bz-Arg-NHC12 was 
increased, a net increment in the SPR signal was evidenced, suggesting an increase in the 
binding of the surfactant molecules to HRBC lipids, which exceeded the decreasing response 
caused by the lipid extraction. As a result, SPR responses in these cases must include both the 
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binding of the surfactant to the surface of the lipid bilayer along with the extraction of the lipids. 
In contrast, a different profile was observed when Bz-Arg-NHC12 was injected on chips covered 
with lipids extracted from SRBC. In this case, after surfactant injection an increase of the SPR 
signal was observed, indicating the binding of Bz-Arg-NHC12 molecules to the immobilized 
lipids (Fig. 6, Panel b). An increment in the binding was detected as the concentration of the 
surfactant increased, evidenced as an increment in the SPR signal. 
When 250 and 500 µM of surfactant were injected, the lower signals obtained in the 
sensorgrams for HRBC lipids compared to those of SRBC lipids suggest the combination of 
both processes —surfactant binding and removal of lipids from the bilayer— occurring 
simultaneously in HRBC membranes. Based on these results, we attribute the decrease of the 
response in the SPR sensorgrams to lipid extraction from the immobilized HRBC lipids. The 
reduction of the signal observed in the case of bilayers consisting of lipids extracted from 
HRBC supports our hypothesis about the alternative mechanism for HRBC resistance against 
hypotonically induced hemolysis in the presence of Bz-Arg-NHC12. Neither microvesicle 
release or lipid extraction by action of the surfactant aggregates were evidenced when the 
surfactant interacted with the bilayers consisting of lipids extracted from SRBC. In this case 
only the association of surfactant molecules with the lipid bilayer seemed to occur. 
 
Fig. 6. SPR sensorgrams obtained with injections of surfactant solutions (125, 250 and 500 µM) 
on supported lipid bilayers made of lipid extracted from HRBC (Panel a) and SRBC (Panel b). 
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Time of the injection at 10 µL/min is pointed with and arrow. SPR signals are normalized to 
the amount of immobilized bilayer. 
By means of a computer-executed multivariate analysis, a comparison has been made between 
the osmotic fragility of mammalian erythrocytes and twenty-three species-specific variables 
[24]. Statistically significant correlations were found between cell fragility and mean cell 
volume, and PC and SM membrane content: while mean cell volume has a direct effect on the 
osmotic response, PC and SM content determines the membrane behavior. Cell volume (the 
only dimensional variable) showed a strong negative correlation (-0.84) with fragility —i.e. 
fragility decreases as cell volume increases. This is not an unexpected phenomenon, as at a 
given hypotonic concentration, the larger the cell, the smaller the percentage increase in volume 
and the later the onset of hemolysis occurs. It is important to note that the mean volume of 
SRBC is lower than that of their human counterparts. Thus, more membrane surface is exposed 
in the first than in the latter. This emphasizes that the differences in susceptibility towards the 
surfactant studied in this paper are due to their composition rather than to differences in surface 
exposure. 
In terms of the membrane lipid composition of the phospholipid fractions, PC appears to have 
a stabilizing influence on the cell membrane, whereas SM correlates significantly with cell 
fragility. These three parameters —cell volume and membrane content of SM and PC— are in 
favor of a greater osmotic fragility of the SRBC in comparison with HRBC. 
SRBC can incorporate a much lower amount of surfactant molecules into the bilayer before the 
protective effect is lost and hemolysis takes place, as seen in Table 1. Previous suggestions 
regarding the effect of surfactants on the resistance of RBC towards hypotonically induced lysis 
are based mainly on the idea that the intercalated molecules increase either the membrane-
area/cell-volume ratio or the stretching capacity of the bilayer, thereby allowing the cell to attain 
a critical hemolytic volume, which would aid in restraining the hypotonic pressure. This would 
permit the cell to swell to a greater volume before it lyses in the hypotonic medium. 
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However, no volume expansion was found when the assay was performed with HRBC, 
although these cells were able to resist a wide range of surfactant concentrations before lysis 
take place. The physicochemical properties of the SRBC membrane, determined by its lipid 
composition (enriched in cholesterol and SM), does not allow the release of microvesicles and 
consequently volume expansion takes place before lysis begins.  
4. CONCLUSIONS 
Human and sheep red blood cells are both susceptible to Bz-Arg-NHC12. The surfactant studied 
in this paper has shown a biphasic behavior protecting RBC against hypotonic hemolysis at low 
concentrations but inducing hemolysis at higher ones. All results suggest that the mechanism 
by which Bz-Arg-NHC12 produces either hemolysis or protects RBC from osmotic lysis seems 
to depend crucially on the lipid composition of the membrane. Briefly, results proved that in 
RBC with membranes with high content of SM and absence of PC —e.g. SRBC—, the 
antihemolytic mechanism involves surfactant monomer insertion into the membrane, leading 
to its enlargement, which allows RBC to swell, increasing its critical lytic volume before lysis 
occurs. However, in RBC with membranes with relatively similar content of PC and SM —e.g. 
HRBC— the volume expansion (cell swelling) induced by monomer insertion is compensated 
via shedding of mixed microvesicles from the membrane or by the extraction of membrane 
components caused by collisions between the cells and the surfactant aggregates present in the 
surrounding medium. Fig. 7 presents a schematic representation of both phenomena. These two 
mechanisms are supported by SPR studies, which have corroborated the interaction of the 
surfactants with the lipid bilayer, and the lipid released from bilayer composed by lipid 
extracted from HRBC. AC
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Fig. 7. Simplified scheme of the main antihemolytic mechanisms observed for Bz-Arg-NHC12 
depending on the RBC membrane composition. While in SRBC (Panel a) —which membrane 
has high content of SM and absence of PC— the surfactant monomer insertion into the 
membrane, leads to its enlargement, allowing SRBC to increase its critical lytic volume, in 
HRBC (Panel b) —which membrane has relatively similar content of PC and SM— the volume 
expansion is compensated via microvesicle release or by the extraction of membrane 
components upon collisions between red blood cells and surfactant aggregates. N.b.: 
microvesicles and mixed micelles are represented in transverse cross section. 
On the basis of our overall results, we conclude that cell volume expansion is not a general 
mechanism for surfactant protection against hypotonic hemolysis, since it depends not only on 
the chemical structure of the surfactant, but —for a given surfactant— on the composition and 
biophysical properties of the cell membrane. 
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SUPPLEMENTARY MATERIAL 
C50 determination 
The assays consisted on the incubation of 25 µL of the erythrocyte suspensions (HRBC and 
SRBC) in the presence of Bz-Arg-NHC12 at the corresponding cAHmax dissolved in PBS of 
different osmolarities (1 mL), ranging from isotonic (300 mOsm/L) to hypotonic (85 mOsm/L) 
solutions, for 10 minutes at 37°C. Control experiments were carried out in the presence of PBS 
at the same osmolarities but in the absence of the surfactant. Hemolysis degrees were 
determined following the procedure previously described and dose-response curves were 
plotted. A sigmoidal (Boltzmann) fit was applied to each plot using the Origin Pro 8® software 
and osmolarities inducing 50% of hemolysis (C50) were obtained (Fig. S1)[15]. 
 
Fig. S1. Osmotic lysis of human (Panel a) and sheep (Panel b) red blood cells in serial dilutions 
of PBS (control) and PBS added with Bz-Arg-NHC12 at the cAHmax (672.1 μM and 336 µM 
respectively). Values are plotted as the mean ± SD of three independent experiments. 
 
Table 1. Concentration inducing 50% hemolysis (HC50), maximum protective concentration 
against hemolysis (cAHmax), antihemolytic potency (pAH), and theoretical calculation of the 
volume expansion (Vol Exp) induced by Bz-Arg-NHC12 
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 HC50 (µM) 
cAHmax 
(µM) 
pAH 
(%) 
Vol Exp 
(%) 
HRBC 1412.8 ± 15.8 672.1 67.32 3.8 ± 0.6 
SRBC 1585.3 ± 26.9 336.1 37.54 15.15 ± 0.7 
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